Autolus Therapeutics experienced two recent insider transactions totaling approximately $31,360 in sales. U.S. CCO Cintia Piccina executed these disposals following the company's latest earnings report, which showed a 28.57% EPS beat. The stock has risen 28.9% over the past ninety days, currently trading near the midpoint of its annual price range.